Generic Name and Formulations:
Exenatide 250mcg/mL; soln for SC inj; contains m-cresol and mannitol.
Indications for BYETTA:
Adjunct to diet and excercise to improve glycemic control in adults with type 2 diabetes.
Limitations Of use:
Not a substitute for insulin. Not for treating type 1 diabetes or ketoacidosis. Not studied in combination with prandial insulin or with a history of pancreatitis.
Give by SC inj into thigh, abdomen, or upper arm within 60 mins before AM and PM meals (or before the 2 main meals of the day, approx. ≥6hrs apart). Initially 5mcg twice daily; may increase to 10mcg twice daily after 1 month. Moderate renal impairment (CrCl 30–50mL/min): caution when initiating or escalating doses from 5mcg to 10mcg.
History of pancreatitis; consider other antidiabetic therapies. Monitor for pancreatitis; if suspected, promptly discontinue; if confirmed, do not restart. Do not reuse or share pens or needles between patients. Severe GI disorders, renal impairment (CrCl <30mL/min), end-stage renal disease: not recommended. Renal transplantation. Pregnancy (Cat.C). Nursing mothers.
Glucagon-like peptide-1 (GLP-1) receptor agonist.
Concurrent prandial insulin: not recommended. Increased risk of hypoglycemia with concomitant sulfonylurea, insulin, or other insulin secretagogues (eg, meglitinides); consider reducing dose of these. May delay absorption of oral drugs (take these 1hr before exenatide). Monitor warfarin.
GI upset, hypoglycemia, feeling jittery, dizziness, headache, dyspepsia, constipation, asthenia, reduced appetite, GERD, hyperhidrosis; antibody formation (glycemic response may be attenuated), pancreatitis (may be fatal), hypersensitivity reactions.
Prefilled pen (needles not included): 5mcg/dose—1 (60 doses); 10mcg/dose—1 (60 doses)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline